Hexagon Capital Partners LLC Has $492,000 Stake in Boston Scientific Corporation (NYSE:BSX)

Hexagon Capital Partners LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 2.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,876 shares of the medical equipment provider’s stock after buying an additional 114 shares during the period. Hexagon Capital Partners LLC’s holdings in Boston Scientific were worth $492,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of BSX. Bank Pictet & Cie Europe AG boosted its position in shares of Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. lifted its stake in Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider’s stock valued at $3,987,000 after buying an additional 6,264 shares during the period. Blue Trust Inc. boosted its holdings in Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider’s stock worth $504,000 after buying an additional 575 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in shares of Boston Scientific by 109.9% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider’s stock worth $24,126,000 after buying an additional 141,398 shares during the period. Finally, Little House Capital LLC bought a new stake in shares of Boston Scientific in the 1st quarter valued at about $945,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president owned 22,235 shares of the company’s stock, valued at $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares of the company’s stock, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 461,970 shares of company stock valued at $47,755,193 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.6%

Boston Scientific stock opened at $104.30 on Friday. The company has a market cap of $154.30 billion, a price-to-earnings ratio of 76.13, a P/E/G ratio of 2.71 and a beta of 0.68. The firm has a 50-day moving average of $103.42 and a 200-day moving average of $100.14. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.53.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. Boston Scientific’s revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.56 earnings per share. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. BTIG Research reissued a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Citigroup reaffirmed a “buy” rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, Morgan Stanley boosted their target price on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Twenty-two research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $116.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.